

SEs leading to a dose reduction, treatment discontinuation or surgery	Number of patients/number of exposed patients (%)	Related treatment	Time to occurrence (months) Mean \pm SD	Number of patients who permanently stopped treatment/number of exposed patients (%)
Cataract	6/36 (17%)	Injected ocular corticosteroids	13.5 \pm 6.9	1/36 (3%)
IOP >21 mmHg	13/36 (36%)	Injected ocular corticosteroids	2.6 \pm 4.1	2/36 (6%)
Weight gain \geq 5 kg	16/141 (11%)	Prednisone	16.3 \pm 19.1	2/141 (1%)
Induced diabetes	4/141 (3%)	Prednisone	17.6 \pm 6.0	2/141 (1%)
Mood disorders	21/141 (15%)	Prednisone	3.8 \pm 4.9	4 /141 (3%)
	7/57 (12%)	IFN	5.7 \pm 7.0	5/57 (9%)
High blood pressure	2 /141 (1%)	Prednisone	18.0 \pm 6.0	0/141
Renal abnormalities	19/42 (45%)	Cyclosporin	13.5 \pm 6.1	5/42 (12%)
Osteoporotic fractures	2/141 (1%)	Prednisone	43.0 \pm 30.0	2/141 (1%)
Transaminases >100 IU	2/73 (3%)	Antimetabolites	12.0 \pm 18.0	2/73 (3%)
	2/57 (4%)	IFN	24.0 \pm 27.0	2/57 (4%)
Thyroiditis	7/57 (12%)	IFN	31.9 \pm 17.1	4/57 (7%)
Lymphopenia	4/73 (5%)	Antimetabolites	18.5 \pm 7.3	1/73 (1%)
	10/57 (18%)	IFN	39.1 \pm 11.8	8/57 (14%)
Severe asthenia	2/73 (3%)	Antimetabolites	3.0 \pm 8.0	2/73 (3%)
	6/57 (11%)	IFN	21.3 \pm 12.2	4/57 (7%)
Severe myalgia	5/57 (9%)	IFN	29.3 \pm 10.1	3/57 (5%)
Gastrointestinal disorders	6/73 (8%)	Antimetabolites	7.5 \pm 6.1	5/73 (7%)
Infection	4/19 (2%)	TCZ	12.5 \pm 3.8	2/19 (11%)
	1/28 (4%)	Anti-TNF	4	1/28 (4%)
Diffuse rash	1/73 (1%)	Antimetabolites	2	1/73 (1%)
Gingivitis	2/42 (5%)	Cyclosporin	12.0 \pm 24.0	2/42 (5%)
	2/28 (7%)	Anti-TNF	8.0 \pm 12.0	1/28 (3.5%)
Non-Hodgking lymphoma	1/42 (2%)	Cyclosporin	60	1/42 (2%)